---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Special populations"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Special populations. Topics: Pediatric use: UK paediatric investigation plan waiver granted in all age groups; Age range of the population studied in the European phase Ib/II study; Pregnancy and breastfeeding: excluded, with contraception required of participants; Hepatic and renal laboratory limits applied at screening. 4 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/special-populations"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Pediatric use: UK paediatric investigation plan waiver granted in all age groups

> “Granting a waiver in all age groups for the listed condition(s)”
> “All subsets of the paediatric population from birth to less than 18 years of age”
> “Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.”

Source: [MHRA paediatric investigation plan waiver decision (2026)](https://cms.mhra.gov.uk//system/files/2026-07/mhra-102322-pip01-26.pdf)

<a id="topic-2.1.2.8-2"></a>

### Age range of the population studied in the European phase Ib/II study

> “Male and female participants 25-65 years of age.”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-2.1.2.8-3"></a>

### Pregnancy and breastfeeding: excluded, with contraception required of participants

> “All female participants of childbearing potential (FOCP) must have a negative serum pregnancy test at Screening, (and Visit 1A, as appropriate), a negative pregnancy urine dipstick at Baseline, and not be breastfeeding. All FOCPs and sexually mature males must be compliant with a highly effective birth control method.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-2.1.2.8-4"></a>

### Hepatic and renal laboratory limits applied at screening

> “Alanine aminotransferase (ALT) >2 × upper limit of normal (ULN)”
> “Total bilirubin >2 × ULN”
> “Creatinine >1.5 × ULN”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-2.1.2.8-5"></a>

### Juvenile Huntington's disease

No evidence found.

<a id="topic-2.1.2.8-6"></a>

### Dosing in hepatic impairment, renal impairment, or older adults

No evidence found.

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
